Development of Transdiagnostic Single-session Treatment

Luleå Tekniska Universitet

Status

Enrolling

Conditions

Stress Disorder

Depression

Anxiety Disorders

Treatments

Behavioral: Transdiagnostic single-session treatment

Study type

Interventional

Funder types

Other

Identifiers

NCT05784259

275863

Details and patient eligibility

About

The goal of this clinical trial is to test a single session treatment program in primary care patients with anxiety and/or depression and/or stress-related issues. The main questions it aims to answer is:

Will the transdiagnostic treatment program decrease symptoms of depression/anxiety/stress?
Will the transdiagnostic treatment program decrease transdiagnostic risk factors?
Will the transdiagnostic treatment program decrease the measured risk factors equally?
Will the transdiagnostic treatment program impact patients with anxiety, depression or stress disorders equally?
Will the transdiagnostic treatment program have long term (6 months post-treatment) effect on transdiagnostic risk factors?
Will the transdiagnostic treatment program have long term (6 months post-treatment) effect on anxiety, depression, or stress-symptoms?
Have the participants been able to generalize the skills taught in the program(qualitative)?
Within group that were treated with single-session treatment and recieved additional care before follow-up, was there a difference in outcome?

Full description

The study investigates the effect of a single-session, 4 hour, transdiagnostic treatment for primary care patientst with depression, anxiety or stress.

The treatment includes, interoceptive exposure, behavioral activation, mindfulness, defusion and psycho-education about emotions.

The study is conducted in a clinical setting in northern sweden and follows up results at 3 weeks and 6 months post treatment.

Enrollment

300 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Meet the criteria for anxiety, mood disorder, or stress diagnosis
Symptoms are mild to moderate in severity

Exclusion criteria

Already in ongoing psychotherapy
Within a month commenced pharmaceutical treatment that will likely impact mood or psychological functioning and is not deemed to be on a stable dose
Has a comorbid personality disorder
Has a risk of suicide deemed other than low
Has other severe psychological disorders outside the scope of primary care
Is in a severely stressful social situation deemed incompatible with psychotherapy